Ireland
--:--IST
Recruiting Not applicable

Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation

NCT06375278 · tracked via the Priya Life Science USA tracker
Phase
Not applicable
Started
2024-09-23
Last updated
2026-07-23

Condition(s) studied

Cochlear ImplantsCochlear ImplantationHearing Loss

Investigational drug(s) / intervention(s)

Intra-Ear Canal Cooling Catheter

Intra-Ear Canal Cooling Catheter: Mild therapeutic hypothermia will be applied via the catheter device installed inside the ear canal by an experienced surgeon during cochlear implantation (CI) surgery.

Study summary

The goal of this interventional clinical study is to investigate the use of mild therapeutic hypothermia for preservation of residual hearing in cochlear implant surgery. The main questions the trial aims to answer are:

1. Is mild therapeutic hypothermia safe for use during cochlear implantation?
2. Is mild therapeutic hypothermia effective at preserving residual hearing after cochlear implantation?

Participants will receive mild therapeutic hypothermia therapy during cochlear implant surgery. Researchers will compare results from those receiving the therapy to those from a control group (individuals receiving no therapy).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Potential participants for the study are patients who have been diagnosed with severe to profound hearing loss (HL) and plan to undergo cochlear implantation (CI) at the University of Miami. The cochlear implant surgery, pre and post-surgical care, and activation and programming of the implant are part of the participants' standard of care. If the inclusion criteria are met (age 18 years and older, equal number of men and women, profound sensorineural hearing loss (for safety study n=6) and residual hearing (see criteria below) from pre-surgical auditory brainstem response (ABR) (for efficacy study n=48), equal numbers of CI devices from all 3 manufactures and English or Spanish speakers the patient will be approached by the study personnel and will be asked to participate in the study. Exclusion Criteria: Subjects under 18 years of age. Subjects not meeting functional hearing requirements. Types of CI devices: The study will enroll patients receiving CI devices from all three manufactures. 1. Advanced Bionics (FDA indications - severe to profound sensorineural hearing loss (greater than or equal to 70 dB HL) 1. HiRes Ultra 3D slim J 2. HiRes Ultra 3D midScala 2. Cochlear Corporation (FDA indications - moderate to profound sensorineural hearing loss; sentence recognition less than or equal to 50% in the ear to be implanted AND less than or equal to 60% in the contralateral ear 1. CI632 2. CI622 3. CI612 3. Med-EL (moderately-severe to severe sensorineural hearing loss (greater than or equal to 65 db HL). 1. Synchrony 2 Flex soft 2. Synchrony 2 Flex28 3. Synchrony 2 Flex 24 4. Synchrony 2 Compressed 5. Synchrony 2 Medium Additional patients receiving devices not listed here may be eligible as the criteria by manufacturer change.

Primary outcome measure(s)

  • Pure Tone Audiometry — At initial cochlear implant activation or 1 month post-operatively; 3 and 12 months post-operatively
    Pure-tone average (PTA) of 125, 250 and 500 Hz which will be tested post-operatively in the safety and efficacy arms to measure residual hearing. A clinically significant change in hearing is greater than 10 dB HL (decibels hearing level) shift.

Trial sites (1)

FacilityCityRegionStatus
University of Miami Miami Florida Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06375278 on ClinicalTrials.gov ↗ ← All trials in the USA